Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis

Background In April 2024-over 40 years after its first approval in Europe-pivmecillinam received approval from the United States Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (uUTI) in women aged >= 18 years, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Herein, we describe the reanalysis from previously published clinical trials, conducted in accordance with current FDA efficacy criteria, which formed the basis for this regulatory approval.Methods Of 14 studies reviewed, 3 randomized, controlled trials offered suitable subject-level data from patients with uUTI treated with 185 mg pivmecillinam 3 times daily for 3-7 days. Efficacy endpoints for reanalysis were rates of overall (composite clinical and microbiological), clinical, and microbiological response in the microbiological intention-to-treat population (urine culture >= 105 colony-forming units/mL;